Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Xinyue Capsule** is a Chinese prescription botanical medicine manufactured by Jilin Jian Yisheng Pharmaceutical. Its declared active ingredient is total saponins extracted from the stems and leaves of *Panax quinquefolius* (American ginseng); each 0.3 g capsule is equivalent to 50 mg of these saponins. It is approved in China for coronary heart disease with angina pectoris in patients classified under the traditional Chinese medicine pattern of qi and yin deficiency. The product has also been studied as an adjunct to conventional therapy after percutaneous coronary intervention and is being evaluated in a Phase 3 study for heart failure with preserved ejection fraction. No single, clinically validated molecular target has been assigned to the standardized multicomponent botanical extract. ([yisheng-pharm.com](https://www.yisheng-pharm.com/productInformation/drugs/capsule/201808/t20180830_5769.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinyue Capsule.